 Connection
David Raben to Papillomaviridae
This is a "connection" page, showing publications David Raben has written about Papillomaviridae.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.507 |
|
|
|
-
O'Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, Lee N, Riaz N, Pei X, Koyfman SA, Adelstein D, Burkey BB, Friborg J, Kristensen CA, Gothelf AB, Hoebers F, Kremer B, Speel EJ, Bowles DW, Raben D, Karam SD, Yu E, Xu W. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016 04; 17(4):440-451.
Score: 0.121
-
Rosenthal DI, Harari PM, Giralt J, Bell D, Raben D, Liu J, Schulten J, Ang KK, Bonner JA. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. J Clin Oncol. 2016 Apr 20; 34(12):1300-8.
Score: 0.119
-
Bowles DW, Reddy K, Wine T, Ree A, Raben D, Chen C, Jimeno A. Locoregional recurrence of an HPV-positive squamous cell carcinoma of the head and neck. Oncology (Williston Park). 2011 Oct; 25(11):1042-8.
Score: 0.089
-
Chung CH, Raben D. p16 Expression as a predictive biomarker of hypoxic cell-sensitizing agents in oropharyngeal cancer. J Clin Oncol. 2010 Sep 20; 28(27):4103-4.
Score: 0.082
-
Fakhry C, Zhang Q, Gillison ML, Nguyen-T?n PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM, Barrett WL, Thorstad WL, Yom SS, Wong SJ, Ridge JA, Rao SSD, Spencer S, Fortin A, Raben D, Harris J, Le QT. Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials. Cancer. 2019 06 15; 125(12):2027-2038.
Score: 0.037
-
Bonner JA, Giralt J, Harari PM, Baselga J, Spencer S, Bell D, Raben D, Liu J, Schulten J, Ang KK, Rosenthal DI. Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial. Eur J Cancer. 2016 09; 64:1-11.
Score: 0.031
-
Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D, Gillison ML, Jordan RC, Le QT. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol. 2014 Dec 10; 32(35):3930-8.
Score: 0.027
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|